BIONEWS
Pairing the decades old antibiotic with a small lab built compound lets it work again in culture dishes, in a strategy researchers are pursuing to rescue retired drugs rather than invent new ones.
A small molecule called pghi-4 doesn't kill bacteria on its own. It blocks an enzyme that vancomycin-resistant Enterococcus faecium (VRE) uses to remodel its cell wall, stripping away the resistance that had made the decades-old antibiotic useless against the hospital superbug. In lab dishes, pairing pghi-4 with vancomycin restored the drug's ability to kill VRE, according to a peer-reviewed Nature Communications paper from Cold Spring Harbor Laboratory and Scripps Research.
The work, led by John Moses at CSHL and Howard Hang at Scripps, treats the antibiotic crisis as a chemistry problem with a chemical solution. Instead of hunting for a brand-new antibiotic, the teams paired an existing drug with a helper that disarms one specific resistance mechanism. The strategy has a name: antibiotic adjuvant therapy, keeping an old drug in service by neutralizing the bacterium's defense.
Vancomycin is the last-resort antibiotic most readers have not heard of. Doctors reach for it when frontline drugs like methicillin fail against severe staph infections, including MRSA, and against Clostridioides difficile colitis. Resistant strains of these pathogens have spread through hospitals, nursing homes, and communities for decades, slowly eroding the antibiotic arsenal.
VRE, the bug in the new study, sidesteps vancomycin by reshaping the peptidoglycan layer in its cell wall, the mesh-like structure the drug binds to in order to kill the bacterium. The remodeled peptidoglycan no longer matches the shape vancomycin recognizes, so the drug slides off and the infection survives.
This is where pghi-4 enters. The molecule inhibits the bacterial enzyme that performs the remodeling, leaving the cell wall in the form vancomycin can still grab. The combination doesn't create a new antibiotic; it removes the resistance that had retired the old one.
The molecule was not designed from scratch. It was identified from a 150-compound library built using diversity-oriented clicking (DOC) chemistry, a method developed in the Moses lab that generates large pools of structurally varied small molecules. Earlier DOC outputs have produced candidates for cancer research and other antibiotic-resistance targets. pghi-4 is a single hit from that library against a single organism, and the broader claim that similar adjuvants can rescue other failing antibiotics is a forward-looking author statement, not an established result.
Vancomycin and pghi-4 were tested against VRE in culture dishes, not in mice and certainly not in patients. The work establishes mechanism and lead optimization, the early chemistry phase in which a promising compound is refined before animal studies. Human trials, if they happen, are years away.
Bacteria mutate; the enzyme pghi-4 inhibits can change, or VRE can acquire an entirely different escape route. The authors describe the work as a template rather than a finished treatment, an example of how antibiotic adjuvants might refill a thinning drug pipeline without the multi-year cost of from-scratch discovery.
The bioRxiv preprint has been public since September 2025; the peer-reviewed version appeared in Nature Communications this month. A CSHL/Scripps release on EurekAlert and a ScienceDaily summary repeat the same mechanism and authorship. The cluster is one paper, four corridors; treating it as a single underlying story is fair.
The economics of new antibiotics are poor and the biology of resistance is relentless. If pghi-4-class molecules can restore multiple retired drugs, the next decade of resistance-fighting may not require inventing new antibiotics at all, only smarter chemistry around the ones already on the shelf.